The weak inhibition of CYP21A2 by oteseconazole and lack of effect on 3β-HSD2 suggest a negligible risk of adrenal insufficiency and hyperplasia via this mechanism (Miller and Auchus, 2011). The gene discussed is CYP21A2; the disease is Adrenal insufficiency.